Literature DB >> 16934755

Phosphorylation of ErbB4 on Tyr1056 is critical for inhibition of colony formation by prostate tumor cell lines.

Richard M Gallo1, Ianthe Bryant, Rachael Fry, Eric E Williams, David J Riese.   

Abstract

We have previously demonstrated that the constitutively active Q646C mutant of the ErbB4 receptor tyrosine kinase inhibits colony formation by human prostate tumor cell lines. Here we use ErbB4 mutants to identify ErbB4 functions critical for inhibiting colony formation. A derivative of ErbB4 Q646 that lacks kinase activity fails to inhibit colony formation by prostate tumor cells. Likewise, an ErbB4 Q646C mutant in the context of the CT-b splicing isoform fails to inhibit colony formation. Mutation of tyrosine 1056 to phenylalanine abrogates inhibition of colony formation whereas an ErbB4 mutant that lacks all of the putative sites of tyrosine phosphorylation except for tyrosine 1056 still inhibits colony formation. Given that tyrosine 1056 is missing in the CT-b isoform, these results suggest that phosphorylation of tyrosine 1056 is critical for function. Indeed, an ErbB4 mutant that lacks kinase activity but has a glutamate phosphomimic residue substituted for tyrosine 1056 inhibits colony formation. Finally, 1-dimensional phosphopeptide mapping indicates that ErbB4 Q646C is phosphorylated on tyrosine 1056. These data suggest that phosphorylation of ErbB4 tyrosine 1056 is critical for coupling ErbB4 to prostate tumor suppression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16934755      PMCID: PMC1618953          DOI: 10.1016/j.bbrc.2006.08.055

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  27 in total

1.  Phosphatidylinositol 3-kinase mediates heregulin-induced growth inhibition in human epithelial cells.

Authors:  A W Hamburger; J Y Yoo
Journal:  Anticancer Res       Date:  1997 May-Jun       Impact factor: 2.480

2.  The cellular response to neuregulins is governed by complex interactions of the erbB receptor family.

Authors:  D J Riese; T M van Raaij; G D Plowman; G C Andrews; D F Stern
Journal:  Mol Cell Biol       Date:  1995-10       Impact factor: 4.272

Review 3.  Epidermal growth factor-related peptides and their receptors in human malignancies.

Authors:  D S Salomon; R Brandt; F Ciardiello; N Normanno
Journal:  Crit Rev Oncol Hematol       Date:  1995-07       Impact factor: 6.312

4.  Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells.

Authors:  Teemu T Junttila; Maria Sundvall; Mikael Lundin; Johan Lundin; Minna Tanner; Pirkko Härkönen; Heikki Joensuu; Jorma Isola; Klaus Elenius
Journal:  Cancer Res       Date:  2005-02-15       Impact factor: 12.701

5.  ErbB kinases and NDF signaling in human prostate cancer cells.

Authors:  A W Grasso; D Wen; C M Miller; J S Rhim; T G Pretlow; H J Kung
Journal:  Oncogene       Date:  1997-11-27       Impact factor: 9.867

6.  Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro.

Authors:  J C Lyne; M F Melhem; G G Finley; D Wen; N Liu; D H Deng; R Salup
Journal:  Cancer J Sci Am       Date:  1997 Jan-Feb

7.  Presenilin-dependent gamma-secretase processing regulates multiple ERBB4/HER4 activities.

Authors:  Gregory A Vidal; Anjali Naresh; Luis Marrero; Frank E Jones
Journal:  J Biol Chem       Date:  2005-03-03       Impact factor: 5.157

8.  Syk- and Lyn-dependent phosphorylation of Syk on multiple tyrosines following B cell activation includes a site that negatively regulates signaling.

Authors:  L M Keshvara; C C Isaacson; T M Yankee; R Sarac; M L Harrison; R L Geahlen
Journal:  J Immunol       Date:  1998-11-15       Impact factor: 5.422

9.  The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone.

Authors:  Christopher C Williams; June G Allison; Gregory A Vidal; Matthew E Burow; Barbara S Beckman; Luis Marrero; Frank E Jones
Journal:  J Cell Biol       Date:  2004-11-08       Impact factor: 10.539

10.  Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patients.

Authors:  A A Memon; B S Sorensen; P Melgard; L Fokdal; T Thykjaer; E Nexo
Journal:  Br J Cancer       Date:  2004-12-13       Impact factor: 7.640

View more
  11 in total

1.  The antibody sc-33040-R fails to specifically recognize phosphorylation of ErbB4 on tyrosine1056.

Authors:  Richard M Gallo; David J Riese
Journal:  Growth Factors       Date:  2007-10       Impact factor: 2.511

2.  The Q43L mutant of neuregulin 2β is a pan-ErbB receptor antagonist.

Authors:  Kristy J Wilson; Christopher P Mill; Richard M Gallo; Elizabeth M Cameron; Henry VanBrocklin; Jeffrey Settleman; David J Riese
Journal:  Biochem J       Date:  2012-04-01       Impact factor: 3.857

3.  ErbB2 Is Necessary for ErbB4 Ligands to Stimulate Oncogenic Activities in Models of Human Breast Cancer.

Authors:  Christopher P Mill; Michael D Zordan; S Michael Rothenberg; Jeffrey Settleman; James F Leary; David J Riese
Journal:  Genes Cancer       Date:  2011-08

4.  Ligand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines.

Authors:  Christopher P Mill; Kathleen L Gettinger; David J Riese
Journal:  Exp Cell Res       Date:  2010-11-24       Impact factor: 3.905

Review 5.  The HER family and cancer: emerging molecular mechanisms and therapeutic targets.

Authors:  Natalia V Sergina; Mark M Moasser
Journal:  Trends Mol Med       Date:  2007-11-05       Impact factor: 11.951

6.  Targeting EGFR with photodynamic therapy in combination with Erbitux enhances in vivo bladder tumor response.

Authors:  Ramaswamy Bhuvaneswari; Yik Yuen Gan; Khee Chee Soo; Malini Olivo
Journal:  Mol Cancer       Date:  2009-11-02       Impact factor: 27.401

Review 7.  Mutational activation of ErbB family receptor tyrosine kinases: insights into mechanisms of signal transduction and tumorigenesis.

Authors:  David J Riese; Richard M Gallo; Jeffrey Settleman
Journal:  Bioessays       Date:  2007-06       Impact factor: 4.345

8.  Nedd4 mediates ErbB4 JM-a/CYT-1 ICD ubiquitination and degradation in MDCK II cells.

Authors:  Fenghua Zeng; Jie Xu; Raymond C Harris
Journal:  FASEB J       Date:  2009-02-04       Impact factor: 5.191

9.  Multiple Functional Motifs Are Required for the Tumor Suppressor Activity of a Constitutively-Active ErbB4 Mutant.

Authors:  Richard M Gallo; Ianthe N Bryant; Christopher P Mill; Steven Kaverman; David J Riese
Journal:  J Cancer Res Ther Oncol       Date:  2013-08-22

10.  A genome-wide association study of breast and prostate cancer in the NHLBI's Framingham Heart Study.

Authors:  Joanne M Murabito; Carol L Rosenberg; Daniel Finger; Bernard E Kreger; Daniel Levy; Greta Lee Splansky; Karen Antman; Shih-Jen Hwang
Journal:  BMC Med Genet       Date:  2007-09-19       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.